1stOncology™: Cancer Intelligence Service – Page 12017 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Protagonist Therapeutics to Announce First Quarter 2020 Financial Results and Provide Corporate and R&D Update

On May 4, 2020 Protagonist Therapeutics, Inc. (Nasdaq:PTGX) reported that it will announce first quarter financial results after the NASDAQ market closes on Thursday, May 7, 2020 (Press release, Protagonist, MAY 4, 2020, View Source [SID1234556980]). Protagonist management will host a conference call to provide a corporate and R&D update at 5:00 p.m. EDT/2:00 p.m. PDT the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Conference Call and Webcast Information

Protagonist executives will host a conference call at 5:00 p.m. EDT/2:00 p.m. PDT on Thursday, May 7, 2020. To access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and refer to conference ID number 4597494. A live and archived webcast of the call will also be accessible in the Investors section of the Company’s website at www.protagonist-inc.com. A replay will be available on the company’s website approximately two hours after the call and will remain available for 60 days.

Amyris To Host First Quarter 2020 Financial Results Conference Call On May 8

On May 4, 2020 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biology solutions provider, owner of Clean Beauty consumer brands and provider of proprietary functional ingredients, reported that the company will host a conference call for investors and analysts on Friday, May 8, 2020 at 6:00 a.m. PT (9:00 a.m. ET) to discuss its first quarter 2020 results (Press release, Amyris Biotechnologies, MAY 4, 2020, View Source [SID1234556979]).

The press release detailing first quarter 2020 results will be issued on the morning of May 8 prior to the call.

On the call, President and Chief Executive Officer John Melo, Chief Financial Officer Han Kieftenbeld, and Chief Operating Officer Eduardo Alvarez will discuss Amyris’ financial results, as well as the company’s business outlook and strategy.

Those who wish to listen to the conference call should dial into (888) 390-3967 (U.S. and International) and ask to be joined to the Amyris, Inc. call. A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit: View Source

If you are unable to listen to the live call, the webcast will be archived on the company’s website. A replay of the webcast will be available on the Investor Relations section of the company’s website approximately two hours after the conclusion of the call.

Insmed Announces Proposed Public Offering of Common Stock

On May 4, 2020 Insmed Incorporated (Nasdaq: INSM) reported that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering (Press release, Insmed, MAY 4, 2020, View Source [SID1234556978]). All of the shares to be sold in the offering are to be sold by Insmed. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

SVB Leerink is acting as sole bookrunning manager for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above has been filed with the Securities and Exchange Commission (SEC), as amended by Post-Effective Amendment No. 1 thereto, and became automatically effective upon filing on May 19, 2017. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering may be obtained, when available, from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, by telephone: 1-800-808-7525, ext. 6218 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

NuVasive to Participate in BofA Securities 2020 Healthcare Conference

On May 4, 2020 NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, reported that management will present at the virtual BofA Securities 2020 Healthcare Conference on Tuesday, May 12 at 5:00 p.m. ET/2:00 p.m. PT (Press release, NuVasive, MAY 4, 2020, View Source [SID1234556977]).

A live webcast of the presentation will be available online from the Investor Relations page of the Company’s website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the live webcast.

Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020

On May 4, 2020 Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that it will host a conference call and webcast on Monday, May 11, 2020 at 5:00 p.m. Eastern Time to review its first quarter 2020 financial and operating results and provide a corporate update (Press release, Marker Therapeutics, MAY 4, 2020, View Source [SID1234556976]).

The webcast will be accessible in the Investors section of the Company’s website at markertherapeutics.com. Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the "Marker Therapeutics First Quarter 2020 Earnings Call."

The archived webcast will be available for replay on the Marker website following the event.